Quantcast

Vyteris Annouces Key Scientific Advisors

August 19, 2008

Vyteris, Inc. (OTCBB: VYTR), manufacturer of the first FDA-approved active patch transdermal drug delivery system and a leader in active transdermal drug delivery technology, announced the formation of a Scientific Advisory Group comprised of four renowned scientists, researchers and clinicians with diverse expertise in active transdermal drug and peptide delivery and central nervous system disorders.

The members of the Scientific Advisory Group are: Russell Potts, PhD, chairperson; Richard Guy, PhD; Randy Mrsny, PhD and Stephen Silberstein, MD, FACP.

“The depth of expertise and breadth of experience of the scientists and practitioners who have joined our Scientific Advisory Group represent key thought leaders in areas important to our field and add extensive pharmaceutical and biomedical experience to Vyteris,” said Haro Hartounian, Ph D., president of Vyteris, Inc. “Their skills and guidance will be invaluable to us as we continue to strive to develop and commercialize new products for active transdermal delivery of pharmaceuticals and specifically peptides.

Notable highlights in the backgrounds of members of the Scientific Advisory Group include:

— Russell Potts, PhD is a recognized expert in the field of iontophoresis. He has published a substantial body of literature, and he is a fellow of the American Association of Pharmaceutical Sciences and the American Institute of Medical and Biological Engineering. He has been involved in the creation of several inventions in the field of iontophoresis and holds more than 25 U.S. patents. He received his Ph.D. in biochemistry from the University of Massachusetts, Amherst, his masters in physical chemistry from Cornell University, and his bachelors in chemistry from Michigan State University. Dr. Potts is also a member of the board of directors at Vyteris;

— Richard Guy, PhD is an internationally renowned expert in the field of iontophoresis and is currently a professor of pharmaceutical science in the Department of Pharmacy and Pharmacology at the University of Bath, United Kingdom. Dr. Guy is also an adjunct professor in the Department of Biopharmaceutical Sciences at the University of California, San Francisco. Dr. Guy received his masters in chemistry from Oxford University and his Ph.D. in pharmaceutical chemistry from the University of London. He is an elected fellow of the Royal Society of Chemistry, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science. He was the first recipient of the Controlled Release Society’s Young Investigator Award in 1988, the same year that he won the British Pharmaceutical Conference Science Award. Dr. Guy was awarded, for his work in iontophoresis, the Prix Applications Medicales de l’Electricite, by the Institut Electricite Sante, Paris, France;

— Randy Mrsny, PhD is currently professor of epithelial biology in the Department of Pharmacy and Pharmacology at the University of Bath, United Kingdom. Dr. Mrsny is also a founder of two biotechnology companies located in the San Francisco Bay Area: Trinity Biosystems and Unity Pharmaceuticals. Previously, Dr. Mrsny headed the drug delivery/biology Group at Genentech, Inc. for 11 years and prior to that, spent three years at ALZA Corporation as the head of peptide biology. Dr. Mrsny received his bachelor’s degree in biochemistry and biophysics at the University of California at Davis and a Ph.D. in anatomy and cell biology at the U.C. Davis School of Medicine; and

— Stephen D. Silberstein, MD, FACP is a professor of neurology at the Jefferson Medical College of Thomas Jefferson University in Philadelphia, Pennsylvania, and director of the Jefferson Headache Center. Dr. Silberstein has been director of the Headache Center since its inception in 1984. He received his doctor of medicine degree in 1967 from the University of Pennsylvania. He trained and did medical research at the National Institutes of Mental Health and has done extensive research and investigational drug studies. There are nearly 200 peer-reviewed articles, book chapters and abstracts resulting from his research. Dr. Silberstein currently serves on the editorial boards of several professional publications including Headache, Topics in Pain Management and Cephalalagia.

The Scientific Advisory Group will meet regularly to provide Vyteris with scientific and clinical guidance for its research, product development, strategic and commercial activities. Additional scientific experts will be consulted with periodically to bring additional capabilities and expertise to assist on the company’s technology and project portfolio.

“I am looking forward to chairing the Scientific Advisory Group, which includes prominent scientists, physicians and opinion leaders,” said Russell Potts, PhD, chairman of the Scientific Advisory Group and a member of Vyteris’ board of directors. “Their experience, perspectives and insights will play an integral role as Vyteris continues to advance its technology and product candidates through pre-clinical and clinical development.”

About Vyteris, Inc.

Vyteris, Inc. is the maker of the first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris’ proprietary active transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. Vyteris recently announced success in non-invasive delivery of a peptide using its system, where the company demonstrated achievement of therapeutic levels of a peptide without using any needles. For more information, please visit our website at www.vyteris.com.

Vyteris Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,”"estimate,”"project,”"anticipate,”"intend,”"plan,”"may,”"will,”"could,”"would,”"should,”"believes,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, statements concerning the potential impact of the new marketing agreement and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others, the competitive environment and competitive responses to the new marketing arrangement. The Company has described other important risks and uncertainties under the caption “Risk Factors” in its most recent Annual Report on Form 10-KSB and in various filings made with the SEC. Actual results may differ materially from those contained in the forward-looking statements in this press release.




comments powered by Disqus